Obesity: Disease Analysis and Forecast

1.1 Market overview
1.2 The obesity market will grow significantly during the forecast period, reaching sales of $118.2 billion in 2035
1.3 Key players will maintain their competitive position
1.4 While the outlook in obesity improves, opportunities remain to improve patient outcomes
1.5 Late-stage pipeline therapies are anticipated to drive growth in the obesity market
1.6 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or staging systems

4.1 Disease background
4.2 Global and historical trends
4.3 Global and historical trends
4.4 7MM forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: total prevalent cases of overweight and obesity
4.4.4 Diagnosed prevalent cases of overweight and obesity
4.4.5 Total and diagnosed prevalent cases of overweight and obesity by BMI class
4.4.6 Total and diagnosed prevalent cases of pediatric obesity by severity
4.4.7 Diagnosed prevalent cases of obesity by comorbidity
4.5 Epidemiological forecast for overweight and obesity (2025-35)
4.5.1 Total prevalent cases of overweight
4.5.2 Total prevalent cases of obesity
4.5.3 Diagnosed prevalent cases of overweight
4.5.4 Age-specific diagnosed prevalent cases of overweight
4.5.5 Sex-specific diagnosed prevalent cases of overweight
4.5.6 Diagnosed prevalent cases of overweight by BMI class
4.5.7 Diagnosed prevalent cases of obesity
4.5.8 Age-specific diagnosed prevalent cases of obesity
4.5.9 Sex-specific diagnosed prevalent cases of obesity
4.5.10 Diagnosed prevalent cases of pediatric obesity by severity
4.5.11 Diagnosed prevalent cases of adult obesity by BMI class
4.5.12 Diagnosed prevalent cases of obesity by comorbidity
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 Limitations of the analysis
4.6.3 Strengths of the analysis

5.1 Diagnosis and treatment overview
5.1.1 Treatment overview
5.2 Key opinion leader insights on disease management
5.2.1 Treatment approach

6.1 Overview

7.1 Overview
7.2 Long-term weight maintenance
7.3 GI tolerability/side-effect burden
7.4 Lean mass preservation and metabolic adaptation
7.5 Cost of therapy
7.6 Specialist capacity and structural prescribing access

8.1 Overview
8.1.1 Multi-receptor agonism
8.1.2 Development of oral agents
8.2 Clinical trials design
8.2.1 Clinical endpoints for obesity
8.2.2 Inclusion and exclusion criteria for obesity

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment

11.1 Overview
11.2 Deal-making trends

12.1 Seven major markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecast methodology
13.4 Primary research- KOLs interviewed for this report
13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologists
13.6.4 Reviewers
13.6.5 Vice President of Disease Intelligence and Epidemiologists
13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

• About the Analyst
• Contact Us

Table 1: Obesity: Key metrics in the 7MM
Table 2: Classifications of obesity as outlined by the WHO
Table 3: Classification systems for obesity based on BMI cutoff points
Table 4: Risk factors and comorbidities for overweight and obesity
Table 5: Treatment guidelines for obesity
Table 6: Top 10 deals by value, 2021-26
Table 7: Obesity market - drivers and barriers in the 7MM, 2025-35
Table 8: Key events impacting sales for obesity in the US, 2025-35
Table 9: Obesity market - drivers and barriers in the US, 2025-35
Table 10: Key events impacting sales for obesity in the 5EU, 2025-35
Table 11: Obesity market - drivers and barriers in the 5EU, 2025-35
Table 12: Key events impacting sales for obesity in Japan, 2025-35
Table 13: Obesity market - drivers and barriers in Japan, 2025-35
Table 14: High-prescribing physicians surveyed, by country

Figure 1: Global sales forecast by country for obesity in 2025 and 2035
Figure 2: Analysis of the company portfolio gap in obesity during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that the Analyst expects to be licensed for the treatment of obesity during the forecast period
Figure 4: Competitive assessment of the late-stage pipeline agents that the Analyst expects to be licensed for the treatment of obesity during the forecast period
Figure 5: Factors involved in the etiology of obesity
Figure 6: Pathophysiological manifestation of obesity
Figure 7: 7MM, total prevalence of overweight, men and women, %, =5 years, 2015-35
Figure 8: 7MM, total prevalence of obesity, men and women, %, =5 years, 2015-35
Figure 9: 7MM, sources used to forecast the total and diagnosed prevalent cases of overweight
Figure 10: 7MM, sources used to forecast the total and diagnosed prevalent cases of obesity
Figure 11: 7MM, sources used to forecast the total and diagnosed prevalent cases of overweight by BMI class
Figure 12: 7MM, sources used to forecast the total and diagnosed prevalent cases of obesity by BMI class
Figure 13: 7MM, sources used to forecast the total and diagnosed prevalent cases of pediatric obesity by severity
Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of obesity by comorbidity
Figure 15: 7MM, total prevalent cases of overweight, N, both sexes, age =5 years, 2025
Figure 16: 7MM, total prevalent cases of obesity, N, both sexes, age =5 years, 2025
Figure 17: 7MM, diagnosed prevalent cases of overweight, N, both sexes, age =5 years, 2025
Figure 18: 7MM, diagnosed prevalent cases of overweight by age, N, both sexes, age =5 years, 2025
Figure 19: 7MM, diagnosed prevalent cases of overweight by sex, N, both sexes, age =5 years, 2025
Figure 20: 7MM, diagnosed prevalent cases of overweight by BMI class, N, both sexes, age =5 years, 2025
Figure 21: 7MM, diagnosed prevalent cases of obesity, N, both sexes, age =5 years, 2025
Figure 22: 7MM, diagnosed prevalent cases of obesity by age, N, both sexes, age =5 years, 2025
Figure 23: 7MM, diagnosed prevalent cases of obesity by sex, N, both sexes, age =5 years, 2025
Figure 24: 7MM, diagnosed prevalent cases of pediatric obesity by severity, N, both sexes, ages 5-17, 2025
Figure 25: 7MM, diagnosed prevalent cases of obesity by BMI class, N, both sexes, age =18 years, 2025
Figure 26: 7MM, diagnosed prevalent cases of obesity by comorbidity, N, both sexes, age =18 years, 2025
Figure 27: BMI chart as a diagnostic technique for obesity
Figure 28: Treatment algorithm for obesity
Figure 29: Unmet needs and opportunities in obesity
Figure 30: Overview of the development pipeline in obesity
Figure 31: Key late-stage trials for the promising pipeline agents that the Analyst expects to be licensed for the treatment of obesity in the 7MM during the forecast period
Figure 32: Competitive assessment of the recently approved agents and late-stage pipeline agents that the Analyst expects to be licensed for the treatment of obesity during the forecast period
Figure 33: Competitive assessment of the pipeline drugs benchmarked against standard of care
Figure 34: Analysis of the company portfolio gap in obesity during the forecast period
Figure 35: 7MM sales forecast by country for obesity in 2025 and 2035
Figure 36: 7MM sales forecast by drug for obesity in 2025 and 2035
Figure 37: Sales forecast by drug class for obesity in the US in 2025 and 2035
Figure 38: Sales forecast by drug for obesity in the 5EU in 2025 and 2035
Figure 39: Sales forecast by drug for obesity in Japan in 2025 and 2035